|
| | Publication Year | Title | Author(s) |
| 41 | 2018 | Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy. | Parakh, Sagun ; Cebon, Jonathan S ; Klein, Oliver |
| 42 | 2018 | Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of IntralesionalBacillus Calmette-Guérinfollowed by Ipilimumab in Patients with Advanced Metastatic Melanoma. | Da Gama Duarte, Jessica; Parakh, Sagun ; Andrews, Miles C; Woods, Katherine; Pasam, Anupama; Tutuka, Candani; Ostrouska, Simone; Blackburn, Jonathan M; Behren, Andreas; Cebon, Jonathan S |
| 43 | 1-Dec-2017 | Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. | Sznol, Mario; Ferrucci, Pier Francesco; Hogg, David; Atkins, Michael B; Wolter, Pascal; Guidoboni, Massimo; Lebbé, Celeste; Kirkwood, John M; Schachter, Jacob; Daniels, Gregory A; Hassel, Jessica; Cebon, Jonathan S ; Gerritsen, Winald; Atkinson, Victoria; Thomas, Luc; McCaffrey, John; Power, Derek; Walker, Dana; Bhore, Rafia; Jiang, Joel; Hodi, F Stephen; Wolchok, Jedd D |
| 44 | Nov-2017 | Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFRβ. | Vella, Laura J; Behren, Andreas; Coleman, Bradley; Greening, David W; Hill, Andrew F; Cebon, Jonathan S |
| 45 | Nov-2017 | Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma | Petrella, Teresa M; Robert, Caroline; Richtig, Erika; Miller, Wilson H Jr; Masucci, Giuseppe V; Walpole, Euan; Lebbe, Celeste; Steven, Neil; Middleton, Mark R; Hille, Darcy; Zhou, Wei; Ibrahim, Nageatte; Cebon, Jonathan S |
| 46 | 5-Oct-2017 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. | Wolchok, Jedd D; Chiarion-Sileni, Vanna; Gonzalez, Rene; Rutkowski, Piotr; Grob, Jean-Jacques; Cowey, C Lance; Lao, Christopher D; Wagstaff, John; Schadendorf, Dirk; Ferrucci, Pier F; Smylie, Michael; Dummer, Reinhard; Hill, Andrew; Hogg, David; Haanen, John; Carlino, Matteo S; Bechter, Oliver; Maio, Michele; Marquez-Rodas, Ivan; Guidoboni, Massimo; McArthur, Grant; Lebbé, Celeste; Ascierto, Paolo A; Long, Georgina V; Cebon, Jonathan S ; Sosman, Jeffrey; Postow, Michael A; Callahan, Margaret K; Walker, Dana; Rollin, Linda; Bhore, Rafia; Hodi, F Stephen; Larkin, James |
| 47 | 7-Sep-2017 | Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. | Ribas, Antoni; Dummer, Reinhard; Puzanov, Igor; VanderWalde, Ari; Andtbacka, Robert H I; Michielin, Olivier; Olszanski, Anthony J; Malvehy, Josep; Cebon, Jonathan S ; Fernandez, Eugenio; Kirkwood, John M; Gajewski, Thomas F; Chen, Lisa; Gorski, Kevin S; Anderson, Abraham A; Diede, Scott J; Lassman, Michael E; Gansert, Jennifer; Hodi, F Stephen; Long, Georgina V |
| 48 | 17-Jul-2017 | Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial | Long, Georgina V; Atkinson, Victoria; Cebon, Jonathan S ; Jameson, Michael B; Fitzharris, Bernie M; McNeil, Catriona M; Hill, Andrew G; Ribas, Antoni; Atkins, Michael B; Thompson, John A; Hwu, Wen-Jen; Hodi, F Stephen; Menzies, Alexander M; Guminski, Alexander D; Kefford, Richard; Kong, Benjamin Y; Babak, Tamjid; Srivastava, Archana; Lomax, Anna J; Islam, Mohammed; Shu, Xinxin; Ebbinghaus, Scot; Ibrahim, Nageatte; Carlino, Matteo S |
| 49 | Jul-2017 | Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. | Abou-Alfa, Ghassan K; Blanc, Jean-Frederic; Miles, Steven; Ganten, Tom; Trojan, Jörg; Cebon, Jonathan S ; Liem, Andre K; Lipton, Lara; Gupta, Charu; Wu, Benjamin; Bass, Michael; Hollywood, Ellen; Ma, Jennifer; Bradley, Margaret; Litten, Jason; Saltz, Leonard B |
| 50 | 28-Jun-2017 | PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. | Tutuka, Candani S A; Andrews, Miles C; Mariadason, John M ; Ioannidis, Paul; Hudson, Christopher; Cebon, Jonathan S ; Behren, Andreas |
| 51 | Jun-2017 | Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases | Parakh, Sagun ; Park, John J; Mendis, Shehara; Rai, Rajat; Xu, Wen; Lo, Serigne; Drummond, Martin; Rowe, Catherine; Wong, Annie; McArthur, Grant; Haydon, Andrew; Andrews, Miles C; Cebon, Jonathan S ; Guminski, Alex; Kefford, Richard F; Long, Georgina V; Menzies, Alexander M; Klein, Oliver ; Carlino, Matteo S |
| 52 | 11-May-2017 | Whole-genome landscapes of major melanoma subtypes. | Hayward, Nicholas K; Wilmott, James S; Waddell, Nicola; Johansson, Peter A; Field, Matthew A; Nones, Katia; Patch, Ann-Marie; Kakavand, Hojabr; Alexandrov, Ludmil B; Burke, Hazel; Jakrot, Valerie; Kazakoff, Stephen; Holmes, Oliver; Leonard, Conrad; Sabarinathan, Radhakrishnan; Mularoni, Loris; Wood, Scott; Xu, Qinying; Waddell, Nick; Tembe, Varsha; Pupo, Gulietta M; De Paoli-Iseppi, Ricardo; Vilain, Ricardo E; Shang, Ping; Lau, Loretta M S; Dagg, Rebecca A; Schramm, Sarah-Jane; Pritchard, Antonia; Dutton-Regester, Ken; Newell, Felicity; Fitzgerald, Anna; Shang, Catherine A; Grimmond, Sean M; Pickett, Hilda A; Yang, Jean Y; Stretch, Jonathan R; Behren, Andreas; Kefford, Richard F; Hersey, Peter; Long, Georgina V; Cebon, Jonathan S ; Shackleton, Mark; Spillane, Andrew J; Saw, Robyn P M; López-Bigas, Núria; Pearson, John V; Thompson, John F; Scolyer, Richard A; Mann, Graham J |
| 53 | 11-Apr-2017 | Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. | Bowyer, Samantha; Prithviraj, Prashanth; Lorigan, Paul; Larkin, James; McArthur, Grant; Atkinson, Victoria; Millward, Michael; Khou, Muoi; Diem, Stefan; Ramanujam, Sangeetha; Kong, Ben; Liniker, Elizabeth; Guminski, Alexander; Parente, Phillip; Andrews, Miles C; Parakh, Sagun ; Cebon, Jonathan S ; Long, Georgina V; Carlino, Matteo S; Klein, Oliver |
| 54 | Mar-2017 | A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant | Davis, Ian D; Quirk, Juliet; Morris, Leone; Seddon, Lauren; Tai, Tsin Yee; Whitty, Genevieve; Cavicchiolo, Tina; Ebert, Lisa; Jackson, Heather; Browning, Judy; MacGregor, Duncan; Wittke, Frederick; Winkels, Gregor; Alex, Regina; Miloradovic, Lena; Maraskovsky, Eugene; Chen, Weisan; Cebon, Jonathan S |
| 55 | 2017 | CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. | Burr, Marian L; Sparbier, Christina E; Chan, Yih-Chih; Williamson, James C; Woods, Katherine; Beavis, Paul A; Lam, Enid Y N; Henderson, Melissa A; Bell, Charles C; Stolzenburg, Sabine; Gilan, Omer; Bloor, Stuart; Noori, Tahereh; Morgens, David W; Bassik, Michael C; Neeson, Paul J; Behren, Andreas; Darcy, Phillip K; Dawson, Sarah-Jane; Voskoboinik, Ilia; Trapani, Joseph A; Cebon, Jonathan S ; Lehner, Paul J; Dawson, Mark A |
| 56 | 1-Dec-2016 | Advance care planning in patients with incurable cancer: study protocol for a randomised controlled trial | Johnson, Stephanie; Clayton, Josephine M; Butow, Phyllis N; Silvester, William; Detering, Karen M ; Hall, Jane; Kiely, Belinda E; Cebon, Jonathan S ; Clarke, Stephen; Bell, Melanie L; Stockler, Martin R; Beale, Phillip; Tattersall, Martin HN |
| 57 | Dec-2016 | Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. | Atkinson, Victoria; Long, Georgina V; Menzies, Alexander M; McArthur, Grant; Carlino, Matteo S; Millward, Michael; Roberts-Thomson, Rachel; Brady, Benjamin; Kefford, Richard; Haydon, Andrew; Cebon, Jonathan S |
| 58 | 16-Nov-2016 | Systems analysis identifies miR-29b regulation of invasiveness in melanoma | Andrews, Miles C; Cursons, Joseph; Hurley, Daniel G; Anaka, Matthew; Cebon, Jonathan S ; Behren, Andreas; Crampin, Edmund J |
| 59 | 9-Sep-2016 | Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations | Grasso, Carole; Anaka, Matthew; Hofmann, Oliver; Sompallae, Ramakrishna; Broadley, Kate; Hide, Winston; Berridge, Michael V; Cebon, Jonathan S ; Behren, Andreas; McConnell, Melanie J |
| 60 | Jul-2016 | Identifying and targeting determinants of melanoma cellular invasion | Jayachandran, Aparna; Prithviraj, Prashanth; Lo, Pu-Han; Walkiewicz, Marzena; Anaka, Matthew; Woods, Briannyn; Behren, Andreas; Cebon, Jonathan S ; McKeown, SJ |
Loading...
2
0
20
0
false
0000-0002-3898-950x